<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13205">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935010</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2016110</org_study_id>
    <nct_id>NCT02935010</nct_id>
  </id_info>
  <brief_title>Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment</brief_title>
  <official_title>Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment：a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With markedly increased antibiotic resistance and unsatisfactory efficacies of common
      empiric eradication regimens in the mainland of China, tailored therapy may be the best
      choice to achieve good efficacy. This study compared the eradication rates, safety, and
      compliance of antibiotic sensitivity-based tailored therapy compared with empiric bismuth
      quadruple therapy in the naive patients with Helicobacter pylori infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>Six weeks after completion of therapy</time_frame>
    <description>Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (&lt;4‰) (4‰ as the cutoff value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>within 7 days after completion of therapy</time_frame>
    <description>During the 14-day treatment period, the subjects kept a diary to score any possible side effects or discomforts. The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as &quot;mild&quot; (transient and well tolerated), &quot;moderate&quot; (causing discomfort and partially interfering with daily activities), or &quot;severe&quot; (causing considerable interference with daily activities). The side effect score recorded was based on the most severe event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>within 7 days after completion of therapy</time_frame>
    <description>Compliance was deﬁned as poor when they had taken less than 80% of the total medication.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Medical cost per patient of tailored or empiric therapy</measure>
    <time_frame>two months after completion of therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ratio of medical cost to H. pylori eradication rate of each therapy</measure>
    <time_frame>two months after completion of therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ratio of incremental medical cost to incremental H. pylori eradication rate of tailored compared with empiric therapy</measure>
    <time_frame>two months after completion of therapy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>proton pump inhibitor</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_label>Empiric therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>Gastric mucosal protective drug with anti-H. pylori effect</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_label>Empiric therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_label>Empiric therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_label>Empiric therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with non-ulcer functional dyspepsia or scarred peptic ulcer disease

          -  Ability and willingness to participate in the study and to sign and give informed
             consent

          -  confirmed H. pylori infection

        Exclusion Criteria:

          -  Previous H. pylori eradication therapy

          -  Less than 18 years old

          -  With history of H. pylori infection treatment

          -  With previous gastric surgery

          -  Major systemic diseases

          -  Pregnancy or lactation

          -  Allergy to any of the study drugs

          -  Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunwei Sun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Gao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yan Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tenth People's Hospital, Tongji University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gang Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai First People's Hospital, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Chen, M.D.</last_name>
    <phone>86+18817821405</phone>
    <email>chenqimd@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lou Yu, M.D.</last_name>
    <phone>86+18202105517</phone>
    <email>531579329@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunwei Sun, M.D.</last_name>
      <email>sun_yunwei@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yunwei Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Xu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Gang Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhao, M.D.</last_name>
      <email>320zhaoyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Yan Zhao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Gao, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hong Gao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingjie Ji</last_name>
      <phone>86+15800575527</phone>
      <email>jiyingjie39@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hong Lu, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Liang, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei zhang, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yingjie Ji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaohua Long, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lou Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huiyi Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weiqi Gu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanyan Song, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>October 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hong Lu, MD</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Bismuth quadruple therapy</keyword>
  <keyword>Tailored therapy</keyword>
  <keyword>Empiric therapy</keyword>
  <keyword>clarithromycin susceptibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
